FDA Inspection
Wyeth BioPharma Division of Wyeth Pharmaceuticals LLCWyeth BioPharma Division of Wyeth Pharmaceuticals LLC – FDA Inspection, Sep 19, 2023
Record Details
This FDA Inspection record concerns Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC, with an inspection on September 19, 2023, issued by the Center for Biologics Evaluation and Research, covering biologics.
- Inspection Date
- September 19, 2023
- Product Type
- Biologics
View Company Profile
ID · f4363d29-0083-495d-94cb-2f6416bd0726
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1218069
- FDA center
- Biologics
- Project area
- Blood and Blood Products
- Outcome
- Form 483 issued
Other FDA inspections of Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC
16| Date | Classification | Office | Project area |
|---|---|---|---|
| August 6, 2026 | Not classified | New England District Office | |
| April 8, 2026 | Not classified | New England District Office | |
| February 11, 2026 | NAI | Human Cellular, Tissue, and Gene Therapies | |
| October 13, 2023 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| May 3, 2019 | Not classified | New England District Office |
Other documents for Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC
- FDA Inspection 1331288 - 2026-08-06
- FDA Inspection 1311392 - 2026-04-08
- FDA Inspection 1304580 - 2026-02-11
- FDA Inspection 1223617 - 2023-10-13
- FDA Inspection 1092777 - 2019-05-03
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.